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A Systematic review and meta-analysis of emergency coronary angiography and
percutaneous coronary intervention in patients who present with cardiac arrest.
Should we implement a standard invasive approach?
Krischan D. Sjauw1, Dagmar M. Ouweneel2, Jose P. Henriques2
1Academical Medical Center - University of Amsterdam, Amsterdam, The
Netherlands, 2Academic Medical Center - University of Amsterdam, Amsterdam, The
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Background: Because of limited data, the indications and timing of coronary
angiography (CAG) and percutaneous coronary intervention (PCI) in patients
with cardiac arrest are controversial. In clinical practice it is often difﬁcult to
determine which patients beneﬁt from early catheterization, with subsequent
PCI. The guidelines promote early catheterization in cardiac arrest patients
with ST-elevation myocardial infarction. However, the predictive value of the
ECG for coronary artery occlusion is poor, especially after cardiopulmonary
resuscitation.
Methods: Medical literature databases were scrutinized to identify randomized trials
comparing CAG vs. no CAG, and PCI vs. no PCI. In absence of randomized trials
cohort studies evaluating emergency CAG and PCI in cardiac arrest were identiﬁed.
Two separate meta-analyses were performed respectively.
Results: The ﬁrst meta-analysis included 16 cohort studies of patients with cardiac
arrest (n¼7709). Early CAG compared to no CAG was associated with an absolute
decrease of in-hospital mortality of 14% [95% conﬁdence interval (CI), 12–16%;
P< 0.0001]. This survival beneﬁt was also observed in subsequent subgroup analysis,
respectively of patients with STEMI or new LBBB, and patients with other ECG
patterns. The second meta-analysis included 11 cohort studies evaluating the effect of
emergency PCI in cardiac arrest patients (n¼3033). Emergency PCI compared to no
PCI was associated with an absolute decrease of in-hospital mortality of 18% [95% CI
14-22%; P< 0.0001].
Conclusions: Both early CAG and PCI, compared to respectively no CAG and PCI
were associated with a survival beneﬁt in patients presenting with cardiac arrest.
This did not differ between patients with STEMI or new LBBB, and patients with
other ECG patterns. The prevalence of coronary heart disease, regardless of pre-
senting ECG pattern, is high. All available observational data evaluating early
CAG and PCI is importantly hampered by bias and confounding; i.e. survival and
physician selection bias. Nonetheless, the results of this study support further
evaluation of a more a more aggressive CAG and PCI strategy than currently
advocated.
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Use of Impella 2.5 for Electrical Stabilization in Acute Myocardial Infarction
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Background: The efﬁcacy of Impella (Abiomed Inc., MA, USA) for electrical insta-
bility in the setting of an acute ST-elevation myocardial infarction (STEMI) isB22 JACC Vol 64/11/Suppl Bunknown. Herein, we present a case series of successful hemodynamic support and
electrical stabilization by an Impella device in the setting of ischemic cardiogenic shock.
Methods: Both patients received guideline-directed medical therapy for
STEMI and support with aggressive ﬂuid resuscitation, intubation and inotropes.
Intra-aortic balloon pump and Impella devices were inserted through the femoral
approach.
Results: A 67-year-old female suffered an acute inferior STEMI with cardiogenic
shock from severe right heart failure. During revascularization, she developed
multiple episodes of ventricular tachycardia (VT)-ﬁbrillation (VF) despite amio-
darone infusion. In light of her hemodynamic and electrical cardiac instability, an
intra-aortic balloon pump (IABP) was inserted. However, she remained in right
ventricular (RV) shock (cardiac index of 1.8 L/min/m2) and required a total of 27
deﬁbrillations. A decision was made to insert an Impella 2.5 as a bridge to RV re-
covery, with dramatic hemodynamic and electrical response. Device was success-
fully removed the following day and she recovered well. A 52 year old male was
admitted in cardiogenic shock secondary to an anterior wall STEMI. Cardiac cath-
eterization revealed a complete occlusion of the left anterior descending coronary
artery. The patient received an IABP due to hemodynamic instability. He subse-
quently required more than 20 deﬁbrillations for VT/VF. The IABP was replaced by
an Impella 2.5 device. The patient was quickly restored to sinus rhythm after Impella
in place. The device was removed 4 days after the procedure and the patient
recovered well.
Conclusions: We report two cases of severe electrical instability with recurrent VT/
VF in the setting of cardiogenic shock secondary to an acute myocardial infarction.
In this limited experience, the Impella left ventricular assist device was able to
achieve electrical stability more effectively when compared to an intra-aortic
balloon pump.Heart Failure Therapies
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Complete revascularization in ischemic heart failure may improve patient
survival
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Background: Heart failure (HF) is the major cause of death in cardiovascular disease,
with coronary artery disease (CAD) remaining its most common cause. STICH trial
has left us with many questions unanswered and most PCI-related trials exclude
subjects with ejection fraction (EF) < 35%. Complete coronary revascularization is
one of key concepts in management of ischemic HF.
Methods: We have retrospectively analyzed 1078 unselected patients with
systolic HF (EF< 35%) hospitalized between 2009-2012. Among them we have
selected a group of non-ACS pts scheduled for coronary angiography (n¼495).
57 CABG-qualiﬁed subjects were excluded from analysis. Pts were divided into
group A (complete revascularization, n¼221) and group B (incomplete revas-
cularization, n¼217). Complete revascularization was assessed angiographic-
ally, deﬁned according to current ESC guidelines (vessels >2mm). Patients
were in 12-month follow-up for rehospitalisation, myocardial infarction and
mortality.
Results: Patient characteristics are presented in table 1. Patients in group A had higher
prevalence or prior PCI (54,3 vs 38,2%, p¼0,001), with no differences in prior CAGB
(20,8 vs 22,1%, p¼ns). The incidence of multi-vessel disease was signiﬁcantly higher
in group B (32,4 vs 68,1%, p< 0,01). There have been no signiﬁcant differences in
PCI strategy in both groups. In follow up 12-month mortality was signiﬁcantly lower
in pts with complete revascularization (10,4 vs 18,43%, p¼0,01). The composite
endpoint of death or MI was also signiﬁcantly in favor of complete revascularization
(11,7 vs 23,5%, p¼0,01).
Conclusions: Our study shows, that in an unselected ischemic HF population complete
revascularization has led to improved survival. If possible, complete revascularization in
HF should be considered, and should be one of the factors determining the selection of
revascularization method, with PCI emerging as a safe and viable option.j September 13–17, 2014 j TCT Abstracts/Heart Failure Therapies
Group A Group B
Sex 177M vs 44F 168M vs 49F
Age 62,411 65,811
Mean EF [%] 28,86,9 27,458
Atrial ﬁbrillation [%, p¼ns] 16,2 18,8
NYHA III & IV [%, p¼ns] 29,8 32,7
Chronic kidney disease stage III-V [%, p¼0,02] 32,3 42,4
Diabetes [%, p¼0,04] 38,4 47,9






342  139 369  92 0.096
NT-Pro-BNP (pmol/L) (n¼9) 193  153 262  210* 0.370
MLWHF score
(n¼10)
54  18 31  17 0.009
Table 1. Predictors of Survival
Survivors Non-Survivors p-value
Age (years) 62.33  6.51 57.00  15.33 0.30
Male Gender (#, %) 2 (67%) 4 (80%) 0.72
BMI (kg/m2) 30.91  4.12 29.90  8.72 0.43
Etiology, ICM (#, %) 2 (67%) 3 (60%) 0.86
DM (#, %) 0 (0%) 3 (60%) 0.06
GFR (mL/min/BSA) 82.00  30.35 39.60  4.39 0.02
Device Size (mm, %) 18 (33%),
25 (33%),
30 (33%)
30 (80%), 35 (20%) 0.03
PA Systolic Pressure
(mmHg)
25.50  6.36 54.60  6.50 < 0.01
PA Mean Pressure
(mmHg)
18.00  0.00 38.40  4.16 < 0.01
PA Saturation (%) 68.40  8.20 49.36  6.68 0.01
D WBC @ 96hr (K/mL) 0.03  0.81 6.40  2.74 < 0.01
D Platelet @ 96hr (K/mL) -32.00  31.42 -168.50  98.69 0.04
D LDH @ 96hr (U/L) 157.67  110.55 2287.75  1223.89 0.02
D Total Bilirubin
@ 96hr (mg/dL)
-3.10  6.42 11.88  6.32 0.01
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Percutaneous Ventricular Restoration (PVR) therapy using the Parachute
Device in Patients with Ischemic Dilated Heart Failure: PARACHUTE III,
European Post Market Trial, Primary Endpoint Results
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Background: Left ventricle (LV) remodeling after anterior wall myocardial infarction
(AWMI) leads to increased LV volumes, myocardial stress, and ultimately heart
failure (HF). Treatment options are limited for these high-risk HF patients.
Methods: Aims: The primary objective is to continue to assess the long term safety
of the CardioKinetix Parachute Implant System in the partitioning of the left
ventricle in patients with heart failure due to ischemic heart disease. One hundred
patients with NYHA class II-IV HF secondary to AWMI, with akinetic or dyski-
netic wall motion abnormality, and LV ejection fraction < 40%, were enrolled in
Europe. The primary endpoint was site-reported procedural and device related
MACE in real world use of the Parachute Implant through 5 years of clinical
follow-up. Secondary endpoints included changes in LVESVi, LVEDVi, 6MWT,
and the number of and time to the combined cardiovascular mortality and morbidity
that includes all cause death, hospitalization for heart failure, myocardial infarc-
tion, and stroke, whichever is earlier, within 6, and 12 months from the date of
implantation of the study device.
Results: As of the last data cut in early 2014, a pooled analysis which included 77 of
the 100 PARACHUTE III patients, showed signiﬁcant reductions (p < 0.05) in
LVESVi and LVEDVi at 1 year as well as a signiﬁcant improvement in the 6MWT
data. One-year follow-up of the full cohort of 100 patients will be available for the
TCT conference in September 2014.
Conclusions: The analysis of the post market data conﬁrms the safety and longer term
efﬁcacy of the Parachute device in treating HF.
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Midterm results of a Novel Interatrial Shunt Therapy for Heart Failure and
Preserved Ejection Fraction
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Background: Approximately 50% of patients presenting with clinical features of
heart failure have a preserved ejection fraction (“HFPEF”). The fundamental
pathophysiologic basis for the HFPEF phenotype is impaired diastolic reserve,
with elevated resting, or rapid increase in LVEDP, LAP and pulmonary artery
pressures during low level physical activity. We report the midterm results of a
novel device intended to lower left atrial pressure by creating a small permanent
atrial septal shunt. Objective: Evaluation of safety and potential beneﬁts of the intra
atrial shunt device (IASDTM) System in patients with symptomatic heart failure
with preserved or mildly reduced ejection fraction, despite appropriate medical
management
Methods: Eleven patients were enrolled under an approved protocol in a prospective
multicenter feasibility study. Key inclusion criteria were: EF > 45%; PCWP at rest
 15 or exercise  25mm Hg;  1 hospitalization for heart failure within prior 12
months, or persistent NYHA Class III/IV for at least 3 months.
Results: Mean age, and EF, were 75 Y, and 57 %, respectively. Most patients had
multiple comorbidities. The IASD Device was successfully implanted in each
patient. Two SAE occurred within 30 days, and both were resolved. At 30-90 days,
PCWP was reduced (4 mmHg, P< 0.001) with no change in CVP, and at 6 months
clinical symptoms had improved (See Table). One year follow-up data will be
presented.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Heart FailConclusions: This initial data demonstrates that the shunt device can be safely
implanted and that midterm clinical improvement can be obtained in patients with
heart failure and preserved or mildly reduced ejection fraction.
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Predictors of Survival in Patients Undergoing Trans-Catheter Aortic Valve
Closure for Signiﬁcant Left Ventricular Assist Device Associated Aortic
Insufﬁciency
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Background: Left ventricular assist devices (LVADs) have been shown to in-
crease survival and quality of life in patients with end-stage congestive heart
failure. However, severe aortic insufﬁciency (AI) can develop in up to 50% of
patients with LVADs at 12 months resulting in signiﬁcant morbidity and mortality.
Trans-catheter treatment of LVAD associated AI has emerged as a potential
alternative to surgical treatment, but long term clinical beneﬁts are yet to be
determined.
Methods: We conducted a retrospective analysis of all patients undergoing trans-
catheter aortic valve closure using an Amplatzer Multi-Fenestrated Septal Occluder
“Cribiform” device (AGA Medical, Plymouth, Minnesota) at our institution be-
tween September 2011 and September 2013 to assess potential clinical and pro-
cedural factors associated with survival. Unpaired student’s t-tests were used to
compare baseline patient demographics and procedural characteristics, as well as
patient outcomes immediately post procedure and at 6 months. A p-value of < 0.05
was considered statistically signiﬁcant.
Results: A total of 8 patients (75% male, median age 59 years) were included in this
analysis. Technical success of the procedure including total cessation of AI without
evidence of coronary compromise was accomplished in 100% of patients with a
6 month survival rate of 38% (3/8). Predictors of survival include the absence of
signiﬁcant co-morbidities such as chronic renal insufﬁciency, smaller occlusion device
placement, and the absence of right heart failure (Table 1).Conclusions: Trans-catheter aortic valve closure successfully treats late severe AI
in LVAD patients, however, the presence or development of right heart failure
portends a worse prognosis. Further studies are needed to investigate the
potential right ventricular failure in patients undergoing trans-catheter aortic
valve closure.ure Therapies B23
